Top-News

GMAC Capital Trust I Fixed Rate Floating Rate Trust Preferred Securities, Series 2 News

Keine aktuellen Kursdaten verfügbar
ISIN: US3618602086
US-Symbol: ALLYpA
Typ: Aktie

GMAC Capital Trust I Fixed Rate Floating Rate Trust Preferred Securities, Series 2 News

12.06.12 - PR Newswire
Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-​Quality Branded Generic Medicines Lilly will increase equity position in ...
11.06.12 - PR Newswire
Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin ...
09.06.12 - PR Newswire
Post-hoc analysis of linagliptin phase 3 data in adults with type 2 diabetes and albuminuria presented
Post-hoc analysis of linagliptin phase 3 data in adults with type 2 diabetes and albuminuria presented New analysis presented at American Diabetes Association's 72nd Scientific ...
09.06.12 - PR Newswire
90-week data suggest sustained glucose reduction and weight loss with investigational SGLT-2 inhibitor, empagliflozin
90-week data suggest sustained glucose reduction and weight loss with investigational SGLT-2 inhibitor, empagliflozin Study evaluating the efficacy and safety of empagliflozin up to ...
09.06.12 - PR Newswire
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company present new linagliptin data at American Diabetes Association's 72nd Scientific Sessions®
Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company present new linagliptin data at American Diabetes Association's 72nd Scientific Sessions® Two phase 3 ...
08.06.12 - PR Newswire
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis - Results presented as a late ...
08.06.12 - PR Newswire
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
Lilly and Incyte's Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis - Results presented as a late ...

Newssuche

Videos

09:10 Uhr
Technical Trading: S&P 500 Short Chance
S&P 500 Short Typ: Turbo Open End WKN: UH45D5 Hebel: 2,11 Laufzeit: OpenEnd Einstieg: Market ... Mehr »